1091 / 1816
Maturing of these trials?
All trials will provide up-dates of results with longer follow up
A meta-analysis is in process
Regarding the DBCG-IMN study, the rigth/left guideline was used 2003-
2014, but the DBCG IMN study reported data only from 2003-2007. Thus
outcome from >5000 patients treated 2008-2014 will be published
(including taxans, trastuzumab, letrozole)
What do we need? Biological information to identify subgroups who do not
need MS-IMN RT